Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Current Leases (2019 - 2025)

Celldex Therapeutics has reported Current Leases over the past 7 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Current Leases at $1.6 million for Q4 2025, up 6.89% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 6.89% YoY), and the annual figure for FY2025 was $1.6 million, up 6.89%.
  • Current Leases for Q4 2025 was $1.6 million at Celldex Therapeutics, roughly flat from $1.6 million in the prior quarter.
  • Over the last five years, Current Leases for CLDX hit a ceiling of $1.8 million in Q1 2022 and a floor of $1.3 million in Q2 2021.
  • Median Current Leases over the past 5 years was $1.5 million (2023), compared with a mean of $1.5 million.
  • Peak annual rise in Current Leases hit 31.57% in 2021, while the deepest fall reached 18.43% in 2021.
  • Celldex Therapeutics' Current Leases stood at $1.7 million in 2021, then decreased by 17.24% to $1.4 million in 2022, then rose by 11.7% to $1.6 million in 2023, then fell by 10.04% to $1.5 million in 2024, then grew by 6.89% to $1.6 million in 2025.
  • The last three reported values for Current Leases were $1.6 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.